PDF(Pubmed)
Abstract：
UNASSIGNED: Pulmonary fibrosis is one of the sequelae of the COVID-19, which seriously affects the quality of life of survivors. Currently, there are no optimal evidence based guidelines targeting this population.
UNASSIGNED: We report a 66-year-old female patient without underlying comorbidities admitted to Changsha Public Health Center because of COVID-19. During hospitalization, she developed co-bacterial infection and acute respiratory distress syndrome, and received broad-spectrum antibacterial therapy, invasive mechanical ventilation and extracorporeal membrane oxygenation. After the acute phase, she developed post-COVID-19 pulmonary fibrosis subsequently treated with pirfenidone. Over 96 weeks after pirfenidone treatment, her modified Medical Research Council Dyspnea level improved to 2 from 4 at discharge. Her 6 minutes walk test distance, total lung capacity, and diffusion capacity for carbon monoxide all increased. Chest CT performed on 2 years after illness onset showed regressing fibrosis. The Hospital Anxiety and Depression Scale, Athens Insomnia Scale, and 36-Item Short Form Health Survey questionnaire all improved.
UNASSIGNED: Post-COVID-19 pulmonary fibrosis is a challenging consequence of COVID-19, and our case suggests that pirfenidone may be an effective treatment option.
UNASSIGNED: We report a 66-year-old female patient without underlying comorbidities admitted to Changsha Public Health Center because of COVID-19. During hospitalization, she developed co-bacterial infection and acute respiratory distress syndrome, and received broad-spectrum antibacterial therapy, invasive mechanical ventilation and extracorporeal membrane oxygenation. After the acute phase, she developed post-COVID-19 pulmonary fibrosis subsequently treated with pirfenidone. Over 96 weeks after pirfenidone treatment, her modified Medical Research Council Dyspnea level improved to 2 from 4 at discharge. Her 6 minutes walk test distance, total lung capacity, and diffusion capacity for carbon monoxide all increased. Chest CT performed on 2 years after illness onset showed regressing fibrosis. The Hospital Anxiety and Depression Scale, Athens Insomnia Scale, and 36-Item Short Form Health Survey questionnaire all improved.
UNASSIGNED: Post-COVID-19 pulmonary fibrosis is a challenging consequence of COVID-19, and our case suggests that pirfenidone may be an effective treatment option.
摘要：
■肺纤维化是COVID-19的后遗症之一，严重影响幸存者的生活质量。目前,没有针对该人群的最佳循证指南.
■我们报告了一名66岁的女性患者，该患者因COVID-19入住长沙市公共卫生中心，没有潜在的合并症。住院期间,她出现了联合细菌感染和急性呼吸窘迫综合征，接受了广谱抗菌治疗,有创机械通气和体外膜氧合。急性期过后,她在接受吡非尼酮治疗后出现COVID-19肺纤维化.吡非尼酮治疗后超过96周，她修改后的医学研究委员会呼吸困难水平从出院时的4提高到2.她6分钟的步行测试距离，肺总容量,一氧化碳的扩散能力都增加了。发病后2年进行的胸部CT显示纤维化消退。医院焦虑抑郁量表,雅典失眠量表，和36项简短形式的健康调查问卷都有所改善。
COVID-19后肺纤维化是COVID-19的一个具有挑战性的后果，我们的案例表明吡非尼酮可能是一种有效的治疗选择。
■我们报告了一名66岁的女性患者，该患者因COVID-19入住长沙市公共卫生中心，没有潜在的合并症。住院期间,她出现了联合细菌感染和急性呼吸窘迫综合征，接受了广谱抗菌治疗,有创机械通气和体外膜氧合。急性期过后,她在接受吡非尼酮治疗后出现COVID-19肺纤维化.吡非尼酮治疗后超过96周，她修改后的医学研究委员会呼吸困难水平从出院时的4提高到2.她6分钟的步行测试距离，肺总容量,一氧化碳的扩散能力都增加了。发病后2年进行的胸部CT显示纤维化消退。医院焦虑抑郁量表,雅典失眠量表，和36项简短形式的健康调查问卷都有所改善。
COVID-19后肺纤维化是COVID-19的一个具有挑战性的后果，我们的案例表明吡非尼酮可能是一种有效的治疗选择。
